Search results
AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges
GuruFocus.com via Yahoo Finance· 2 hours agoOncology Portfolio Revenues: $1.543 billion, an increase of 9.0% on a reported basis, driven by...
New Haven and neuroscience: Match made in heaven?
Hartford Business Journal· 12 hours agoThe announcement last spring by Yale New Haven Health of plans to develop an $838 million neurosciences facility on its St. Raphael campus marked New...
Alto Neuroscience schizophrenia treatment shows good phase 1 results
Seeking Alpha· 3 days agoALTO-101, a PDE4 inhibitor by Alto Neuroscience, shows promising results in phase 1 trial for...
To be better at neuroscience, Biogen will invest outside the therapeutic area
FierceBiotech· 2 days agoTo be a better neuroscience company, Biogen is going to have to diversify—outside of the therapeutic...
AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
Investor's Business Daily· 24 minutes agoBotox as a cosmetic treatment brought in $633 million in sales and missed forecasts for $689...
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In...
Benzinga via Yahoo Finance· 3 days agoRecently listed Alto Neuroscience Inc (NYSE:ANRO) released results from its healthy volunteer Phase...
Alto Neuroscience reports positive Phase 1 results for ALTO-101 By Investing.com
Investing.com· 3 days agoAlto Neuroscience, Inc. (NYSE: ANRO) announced today that its Phase 1 study of ALTO-101, a novel...
Opinion: Is social media rewiring kids' brains? Here's what the science really says
Los Angeles Times· 5 hours agoAmerica’s young people face a mental health crisis, and adults constantly debate how much to blame...
PhaseV and Quanticate partner to help sponsors run more adaptive trials
Clinical Trials Arena via Yahoo Finance· 56 minutes agoAdaptive trials are used in nearly every therapeutic area to promote more efficient and precise...
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical...
Morningstar· 2 days ago...Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), along with the Centre for Human Drug Research (CHDR), will present its Phase 1 stroke...